| Literature DB >> 29168771 |
Kaveh Movlaee1,2, Mohmmad Reza Ganjali3, Parviz Norouzi4, Giovanni Neri5.
Abstract
Iron oxide nanostructures (IONs) in combination with graphene or its derivatives-e.g., graphene oxide and reduced graphene oxide-hold great promise toward engineering of efficient nanocomposites for enhancing the performance of advanced devices in many applicative fields. Due to the peculiar electrical and electrocatalytic properties displayed by composite structures in nanoscale dimensions, increasing efforts have been directed in recent years toward tailoring the properties of IONs-graphene based nanocomposites for developing more efficient electrochemical sensors. In the present feature paper, we first reviewed the various routes for synthesizing IONs-graphene nanostructures, highlighting advantages, disadvantages and the key synthesis parameters for each method. Then, a comprehensive discussion is presented in the case of application of IONs-graphene based composites in electrochemical sensors for the determination of various kinds of (bio)chemical substances.Entities:
Keywords: electrochemical sensors; hematite; iron oxide; maghemite; magnetite; synthesis
Year: 2017 PMID: 29168771 PMCID: PMC5746896 DOI: 10.3390/nano7120406
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Crystal structures of (a) hematite and (b) magnetite. Reproduced with permission from [3]. Elsevier, 2009.
Figure 2TEM (transmission electron microscopy) pictures of iron oxide nanoparticles obtained at a reactor temperature of 573 K and residence time of 12 s: (a) iron feed 0.03 M; (b) iron feed 0.50 M. Reproduced with permission from [25]. Cambridge University Press, 2011.
Figure 3(a–c) TEM images and size distributions of Fe3O4 nanoparticles (NPs) with the different mean diameters of 20 nm, (a) σ = 16%, 25 nm (b) σ = 19% and 40 nm (c) σ = 10%. The size distributions show that the synthesized Fe3O4 NPs had a narrow size distribution. (d) Electron diffraction (ED) patterns of the 20-nm Fe3O4 NPs. Reproduced with permission from [27]. American Chemical Society, 2008.
Figure 4Generalized scheme for the preparation of α-Fe2O3, γ-Fe2O3 and Fe3O4 nanoparticles. Reproduced with permission from [29]. Elsevier, 2013.
Figure 5Schematic representation of nanoparticle synthesis in microemulsions (a) by mixing two microemulsions; (b) by adding a reducing agent; and (c) by bubbling gas through the microemulsion. Reproduced with permission from [3]. Elsevier, 2009.
Figure 6TEM micrographs and size histograms for Fe3O4 nanoparticles prepared by microemulsion method at 70 °C in (a) SDS; (b) Brij30; (c) DTAB; (d) DEAB; (e) DBAB; (f) CTAB; (g) 12-2-12. The scale bar is 20 nm. Reproduced with permission form [34]. Elsevier, 2013.
Different methods for IONs preparation, advantages, disadvantages and effective parameters.
| Method | Effective Parameters | Advantages | Disadvantages |
|---|---|---|---|
| Hydrothermal | Pressure | environmental friendly | need to costly autoclave |
| Sol-gel | rates of condensation and hydrolysis | homogenous and high adhesion products | product contains sol–gel matrix components |
| Coprecipitation | concentration of cations | simplest, cheapest and environmental friendly | limited by the boiling point of water |
| Microemulsion | water to surfactant ratio | uniform properties | surfactants are difficult to remove |
Figure 7Allotropes of carbon and their crystal structures. Reproduced with permission from [36].
Figure 8A comparative demonstration of published papers (since 2010 to date) according to Scopus data base searching “graphene” in title. (A) published papers since 2010; (B) categorized published papers in the first 8 scientific areas according to number of papers.
Figure 9(a) Chemical route to synthesize aqueous graphene dispersions; (b) The expected chemical structure of a single sheet of graphene oxide (GO); (c) AFM (atomic force microscopy) image of the GO on a silicon substrate showing an average thickness of around 1 nm. Reproduced with permission from [45]. Royal Society of Chemistry, 2012.
Figure 10A process flow chart of graphene synthesis. Reprinted with permission from [38].
Figure 11Screen printed electrochemical (SPE) sensor typology. (a) conventional SPE; (b) modified SPE. Working electrode where the electrochemical reactions happen and the electrical circuit connection are also shown.
Application of IONs-graphene composite in biochemical determination.
| Iron Oxide | Composite | Analyte(s) | Linear Dynamic Range (LDR) | Limit of Detection (LOD) | Stability | Real Sample(s) | Reference |
|---|---|---|---|---|---|---|---|
| Fe2O3/N-rGO 1 | Dopamine | 0.5 μM to 0.34 mM | 0.49 μM | 82% of its initial current response after twenty days | Dopamine hydrochloride injection | [ | |
| Fe2O3-rGO | Honokiol | 1.5 × 10−8~3.3 × 10−5 M | 9.64 × 10−9 M | - | Traditional Chinese medicine | [ | |
| Magnolol | 7.5 × 10−8~2.6 × 10−5 M | 1.05 × 10−8 M | |||||
| Fe2O3/rGO | AA 2 | 0.57–3.97 mM | 0.543 μM | 85.3% of the initial currents after 2 weeks | - | [ | |
| PEDOT 3-rGO-Fe2O3 | Catechol | 4 × 10−8 to 6.20 × 10−5 M | 7 × 10−9 M | More than 75 days | Green tea | [ | |
| NSG-Fe2O3 4 | Dopamine | 0.3–210 μM | 0.035 μM | 91% of initial current after 7 days | Urine sample | [ | |
| Fe2O3/N-rGO | 0.2–400 μM | 0.1 μM | 90.6% of initial current after 7 days | Syrup | [ | ||
| Fe2O3/rGO | Rutin | 1.5 × 10−8 to 1.8 × 10−5 M | 9.8 × 10−9 M | - | Tablets | [ | |
| PANi 5-Fe2O3-rGO | Hydroquinone | 1.0 × 10−7–5.5 × 10−4 M | 6.0 × 10−8 M | 95.17% of the initial currents after 3 weeks | Tab water | [ | |
| GS-Fe2O3-CTAB 6 | Bisphenol A | 5.0 × 10−9–1.0 × 10−6 M | 2.5 nM | - | Water samples | [ | |
| Fe2O3/rGO | Lysozyme | 0.5 ng·mL−1–5 μg·mL−1 | 0.16 ng·mL−1 | 95.52% of initial current after 10 days | - | [ | |
| Fe2O3-rGO/CS 7 | Gallic acid | 1.0 × 10−6 to 1.0 × 10−4 M | 1.5 × 10−7 M | More than one week | Red and white wines | [ | |
| AuNPs/MrGO 8 | Cortisol | 0.1 to 1000 ng/mL | 0.05 ng/mL | 90.16% of initial current after 20 days | Human serum | [ | |
| Fe3O4-rGO/nafion | Lobetyolin | 1.0 × 10−7–1.0 × 10−4 M | 4.3 × 10−8 M | 93.62% of initial current after 14 days | Radix Codonopsis | [ | |
| H-Fe3O4@C/GNS 9 | Dopamine | 0.1 to 150 μM | 0.053 μM | More than 15 days | Rat brain tissue and urine | [ | |
| Uric acid | 1.0 to 100 μM | 0.41 μM | |||||
| (Fe3O4/rGO) and MIL@MIP 10 | Methamidophos and Omethoate | 1.0 × 10−7–1.0 × 10−12 M and 1.0×10−7–1.0×10−13 M | 2.67 × 10−13 M and 2.05 × 10−14 M | 94.5% of initial current after 15 days | Cucumber and kidney bean samples | [ | |
| Fe3O4-GO | PSA and PSMA 11 | 1.25–1000 pg/mL and 9.7–5000 pg/mL | 1.25 pg/mL and 9.7 pg/mL | 80% of initial current after 4 days | Prostate cancer patient serum samples | [ | |
| Fe3O4-rGO | Glucose | 0.05 to 1 mM | 0.1 μM | 95.6% of initial current after one month | - | [ | |
| Fe3O4-SiO2/GO | Uric acid | 0.5 to 250.0 μM | 0.07 μM | - | Urine sample | [ | |
| GS-Fe3O4/Au@Ag 13 | CEA 14 | 0.1 pg/mL to 100 ng/mL | 0.0697 pg/mL | More than 2 weeks | Human serum samples | [ | |
| AuM/N-rGO 15 | Leukemia cancer cells | 10 to 1 × 106 cell mL−1 | 10 cell mL−1 | - | Human blood plasma | [ | |
| CB/Fe3O4-GO 16 | Chlorpyrifos | 0.1–105 ng/mL | 0.033 ng/mL | 91.2% of initial current after 20 days | Leafy vegetable | [ | |
| Fe3O4@SiO2/GO | Methyldopa (MD) | 0.1–400.0 µM | 86.0 nM | - | MD tablet and urine samples | [ | |
| Fe3O4-rGO | Sulfonamide | 5 × 10−7~1.1 × 10−4 M | 5.0 × 10−8 M | [ | |||
| Fe3O4-GO/carbon nanotube | Salicylic acid | 5.00 to 155 µM | 900 nM | - | Water sample | [ | |
| magnetic bead-GO/IGZO 17 | Glucose | 3–7 mM | - | - | - | [ | |
| Nafion/Mb-SA-Fe3O4-GR/CILE 18 | Trichloroacetic acid | 1.4 to 119.4 mM | 0.174 mM | - | - | [ | |
| 3D NG-Fe3O4 | DNA | 1.0 × 10−14 to 1.0 × 10−6 M | 3.63 × 10−15 M | 90% of initial current after 2 weeks | Serum samples | [ | |
| Fe3O4-SnO2-Gr | AA | 0.1 to 23.00 μM | 62.0 nM | More than 4 weeks | Biological fluids—pharmaceutical samples | [ | |
| DA | 0.02 to 2.8 μM | 7.1 nM | |||||
| UA | 0.015 to 2.40 μM | 5.0 nM | |||||
| Fe3O4@GQD/f-MWCNTs | Progesterone | 0.01–0.5 and 0.5–3.0 μM | 2.18 nM | 85% of initial current after 6 weeks | Serum samples—pharmaceutical products | [ | |
| Alginate/Fe3O4-rGO | Tetracycline | 1 nM to 5 μM | 0.6 nM | 95.86% of initial current after 2 weeks | Food, environmental and clinical samples | [ | |
| TSA-doped PPy/Fe3O4/rGO | Dopamine | 7.0–2.0 μM | 2.33 nM | More than 10 days | Urine and serum samples | [ | |
| Pt-Fe3O4/rGO | Cysteine | 0.10 to 1.0 mM | 10 μM | More than 2 weeks | - | [ | |
| Fe3O4-rGO | Chlorpyrifos | 0.05 to 100 μg/L | 0.02 μg/L | - | Vegetable samples | [ | |
| PS/Fe3O4-GO-SO3H 19 | Doxorubicin | 4.3×10−8 to 3.5×10−6 M | 4.9 nM, 14 nM and 4.3 nM | - | Plasma, cerebrospinal fluid, urine | [ | |
| 8.6×10−7 to 13×10−6 M | |||||||
| 2.6×10−8 to 3.5×10−6 M | |||||||
| Pt/Fe3O4/rGO | NADH 20 | 0.03–1.5 nM | 5 nM | - | - | [ | |
| Fe3O4-rGO | Dopamine | 0.010 and 0.270 μM | 5 nM | 93.5% of initial current after 30 days | Urine sample | [ | |
| GO/CS-Fc 21 | CEA 22 | 0.001–30 ng·mL−1 | 0.39 pg | - | Human serum | [ | |
| ILFSGo 23 | Ascorbic acid | 1.0 × 10−6 to 9.0×10−4 M | 2.3 × 10−7 M | - | - | [ | |
| Fe3O4-rGO | Nitrofuranzone | 1.0 × 10−5 to 1.09×10−4 M | 2.92 × 10−7 M | - | - | [ | |
| Semicarbazide | 1.0 × 10−6 to 1.09×10−4 M | 6.17 × 10−7 M | |||||
| Fe3O4-Co3O4/rGO | Dopamine | 5 × 10−7 to 1.55×10−3 M | 1.3 × 10−7 M | More than 2 weeks | Human serum samples | [ | |
| Uric acid | 1.5 × 10−6 to 1.6 × 10−3 M | 1.8 × 10−7 M | |||||
| rGO/AuNP/Ab2/S/IMB 24 | Salmonella pullorum | 102 to 106 CFU·mL−1 | 89 CFU·mL−1 | - | Chicken liver | [ | |
| GQD-Fe3O4/CNT 25 | L-DOPA | 3.0 to 400 μM | 14.3 nM | - | Seeds and fava bean | [ | |
| Fe3O4-rGO | Adenine | 0.05–25 μM | 4 nM | More than 20 days | Fish, urine samples and vitamin B4 tablet | [ | |
| Guanine | 0.05–25 μM | 3 nM | |||||
| Fe3O4 @ZIF-8 26/RGO | Dopamine | 2.0 × 10−9 to 1.0 × 10−5 M | 6.67 × 10−10 M | More than 10 days | Urine and serum samples | [ | |
| Pd–Fe3O4-GS | immunoglobulin G | 5 × 10−6 to 5 ng/mL | 3.2 fg/mL | More than one month | Human serum samples | [ | |
| Fe3O4-GO/MIP 27 | interleukin-8 | 0.1 to 10 pM | 0.04 pM | 92.9% of initial current after 1 month | Saliva | [ | |
| Fe3O4-GO@AuNPs-MIP | Dibutyl phthalate | 2.5 × 10−9 to 5.0 × 10−6 M | 8×10−10 M | 96.3% of initial current after 4 weeks | Drink samples | [ | |
| AuNPs/Fe3O4-APTES 28-GO | Catechol | 2–145 μM | 0.8 μM | 90% of initial current after 5 days | Tap water | [ | |
| Hydroquinone | 3–137 μM | 1.1 μM | |||||
| MGLA 29 | APOA2 protein 30 | 0.19 to 1.95 μg·mL−1 | 6.7 pg·mL−1 | About 80% decrease after one week | Human urine | [ | |
| DPSPP 31/rGO/Fe3O4 | Hydrazine | 120.0–600.0 nM | 40.0 nM | - | Water samples | [ | |
| Hydroxylamine | 10–155.0 μM | 3.4 μM | |||||
| rGO/Fe3O4 | Melatonin | 0.02–5.80 μM | 8.40 × 10−6 M | - | Pharmaceutical and biological fluids | [ | |
| Dopamine | 0.02–5.80 μM | 6.50 × 10−6 M | |||||
| GS-Nf 32/Au-Fe3O4 | Clenbuterol | 0.5 ng·mL−1 to 200 ng·mL−1 | 0.22 ng/mL | 92% of initial current after 4 weeks | Pork sample | [ | |
| GS-Au-Fe3O4 | 146 antigen (CD146) | 5 pg·mL−1 to 500 ng·mL−1 | 2.5 pg·mL−1 | More than 2 months | Human serum samples | [ | |
| rGO/Fe3O4 | Ascorbic acid | 1–9 mM | 0.42 μM | - | - | [ | |
| Dopamine | 0.5–100 μM | 0.12 μM | |||||
| CS-Fe3O4-GO | Hydroquinone | 1.5 to 150 μM | 20 nM | 95% of initial current after 2 weeks | Tap water | [ | |
| Catechol | 1 to 410 μM | 250 nM | |||||
| GS-Nf/Au-Fe3O4 | chloramphenicol | 2.0 ng/mL to 200.0 ng/mL | 0.82 ng/mL | 93.2% of initial current after one month | Milk sample | [ | |
| Fe3O4-GO-SO3H | Furosemide | 20–100 μM (serum) | 0.1 μM | 92.5% of initial current after 20 days | Human serum and urine | [ | |
| 18–720 μM (Urine) | 0.11 μM | ||||||
| Iron/nickel oxide nanoparticles-graphene | Orange II | 5.0 Nm–3.0 μM | 2.0 nM (for all) | - | Different kinds of food samples | [ | |
| Allura red and Amaranth | 5.0 nM–10.0 μM and 5.0 nM–5.0 μM | ||||||
| rGO/Fe3O4 | 0.10–10.0 mM | 11.1 mM | 93.8% of initial current after 2 weeks | - | [ | ||
| rGO/Fe3O4 | Sudan I | 0.008 μM to 6 μM | 0.5 nM | - | Food samples | [ | |
| Multi-functionalized magnetic graphene sphere | Thyroxine | 0.05 pg·mL−1 to 5 ng·mL−1 | 15 fg·mL−1 | 85.3% of initial current after 20 days | - | [ | |
| Gr-chitosan/Fe3O4 | Guanosine | 2.0 × 10−6 to 3.5 × 10−4 M | 7.5 × 10−7 M | 90.75% of initial current after 15 days | Urine samples and traditional Chinese medicines | [ |
1 Fe2O3/nitrogen-doped Rgo; 2 Ascorbic Acid; 3 Poly (3,4-ethylenedioxythiophene); 4 Nitrogen and sulfur dual doped graphene supported Fe2O3; 5 Polyaniline; 6 Hexadecyltrimethylammonium bromide; 7 Chitosan; 8 Gold nanoparticles-magnetic functionalized reduced graphene oxide; 9 Carbon-encapsulated hollow Fe3o4/GO nanosheets; 10 MIL@MIP film as recognition element; 11 Prostate specific antigen And prostate specific membrane antigen; 12 LDR and LOD were tunable; 13 Magnetic graphene loaded gold and silver core-shell nanoparticles; 14 Carcinoembryonic antigen; 15 Gold-coated magnetic nanoparticles on a nitrogen-doped graphene; 16 Carbon black (CB) and graphene oxide@ Fe3o4; 17 Indium gallium zinc oxide; 18 Myoglobin (Mb), sodium alginate (SA)-Fe3O4-GR composite on the carbon ionic liquid electrode; 19 Magnetic graphene oxide grafted with chlorosulfonic acid (Fe3O4-GO-SO3H) in the presence of polystyrene; 20 Dihydronicotinamide adenine dinucleotide; 21 Graphene oxide/chitosan-ferrocene; 22 Carcinoembryonic antigen; 23 Ionic liquid-magnetic core-shell Fe3O4@SiO2/graphene oxide; 24 Immunomagnetic beads; 25 Immunomagnetic beads; 26 Zeolitic imidazolate framework-; 27 Molecularly imprinted polymer; 28 (3-Aminopropyl) triethoxysilane; 29 Magnetic graphene with longchain acid groups; 30 Apolipoprotein A II protein; 31 1-[2,4-Dihydroxy-5-(phenylazo-4-sulphonic acid)phenyl]-1-phenylmethanon; 32 Graphene sheets (GS)-Nafion (Nf) film.
Figure 12Scanning electron microscopy (SEM) images of (a) GO; (b) Fe3O4 NPs; (c) RGO-Fe3O4 nanocomposite and (d) RGO-Fe3O4/Gox nanocomposite. Reproduced with permission from [78]. Elsevier, 2017.
Figure 13Differential pulse voltammograms at bare GCE (a); GS/GCE (b); Fe3O4-NH2@GS/GCE (c). Reproduced with permission from [130]. Elsevier, 2014.
Figure 14Cyclic voltammograms obtained at GCE, GO/GCE, Fe2O3/GCE and Fe2O3/NrGO/GCE in pH 7.5 PBS in the presence of 0.05 mM DA at a scan rate of 100 mV·s−1. Reproduced with permission from [13]. Elsevier, 2017.
Figure 15Preparation of β-CD-GO/Fe3O4 (MGO-CD) nanocomposites and the β-CD-GO/Fe3O4/GCE (MGO-CD/GCE). Reproduced with permission from [131]. Elsevier, 2016.
Figure 16DPVs of bare GCE, GO/GCE, Fe3O4/GCE and Fe3O4-GO/GCE in the presence of 20 mM of guanine and adenine in 0.1 M phosphate buffer solution (pH 7). Reproduced with permission from [104]. John Wiley and Sons, 2015.
Figure 17Fabrication process for 3D N-G/Fe3O4 hydrogels; (A) photographs of the mixture of GO, FeCl3·6H2O and urea in water (before) and reduction and self-assembly of GO to form the 3D gel with embedded Fe3O4 nanoparticles (after); (B) the N-G/Fe3O4 hydrogel; (C) the aerogel of N-G/Fe3O4 obtained after freeze-drying and thermal treatment; (D) Fabrication and detection process of the DNA biosensor. Reproduced with permission from [88]. Elsevier, 2017.
Figure 18(A) TEM image of CB-CS; (B) HR-TEM micrographs of CB nanostructure; (C) SEM image of GO; (D) SEM image of GO@Fe3O4. Reproduced with permission from [82]. Elsevier, 2017.
Figure 19Fabrication and modification process of the sensor. Reprinted with permission from [94].
Figure 20Schematic diagram of the electrochemical immunosensor apparatus (A) and the detection principle of CLB with competitive immunoassay mode (B). Reproduced with permission from [113]. Elsevier, 2014.
Figure 21DPVs of the immunosensor incubated in PBS containing 0 (a), 0.5 (b), 2.0 (c), 5.0 (d), 20.0 (e), 50.0 (f), 100.0 (g), 200.0 (h) ng/mL of CLB, 2.0 ng/mL anti-CLB and 2 mmol/L K3[Fe(CN)6] at 35 °C for 15 min. Inset: The calibration curve of the current values vs. Concentration of CLB. Reproduced with permission from [113]. Elsevier, 2014.
Figure 22Schematic illustration of the preparation of the immunosensor and the principle of the electrochemical detection. Reproduced with permission from [98]. Elsevier, 2016.